GrayMatters Health develops neurofeedback systems designed to support treatment of mental health conditions through self-regulation of brain activity. The company’s flagship platform, Prism, is an FDA-cleared system that uses electroencephalography (EEG) to guide therapeutic training. Its approach focuses on helping patients learn to modulate neural networks associated with emotional regulation. GrayMatters Health positions its technology within regulated clinical care rather than consumer wellness.

The technology records EEG signals and extracts biomarkers linked to functional brain networks involved in mood and stress regulation. These biomarkers are used to provide real-time feedback during structured neurofeedback sessions, enabling patients to adjust their brain activity through guided training. The system emphasizes network-level modulation rather than single-region activation. This feedback-driven approach is designed to support durable changes in neural regulation over repeated sessions.

GrayMatters Health targets clinical treatment of post-traumatic stress disorder and depression. The Prism system is intended for use by clinicians within therapeutic programs rather than independent home use. Its positioning reflects broader interest in biomarker-guided neurofeedback as a tool for personalized, non-pharmacological mental health treatment.